-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Hebei Provincial Drug Administration Conducts a Visit and Research Tour at Shijiazhuang No. 4 Pharmaceutical Group
Category:
发布时间：2025-08-28
【概要描述】
Recently, Wang Fengshan, Party Secretary and Director of the Hebei Provincial Drug Administration, led officials from the departments of regulatory review and approval, drug registration, and chemical pharmaceuticals supervision on an in-depth field visit to several biopharmaceutical enterprises. During the visit, they conducted on-site inspections, listened to stakeholders’ views, addressed challenges, and actively supported enterprises in pursuing innovative, high-quality development, thereby promoting the quality improvement and upgrading of Hebei’s pharmaceutical industry.
Recently, Wang Fengshan, Party Secretary and Director of the Hebei Provincial Drug Administration, led officials from the departments of regulatory review and approval, drug registration, and chemical drug supervision on an in-depth visit and field inspection of several biopharmaceutical enterprises. During these visits, they ascertained the actual situation, listened to stakeholders’ views, and addressed key challenges, thereby actively supporting enterprises in pursuing innovative, high-quality development and promoting the quality improvement and upgrading of Hebei’s pharmaceutical industry.
On August 13, Wang Fengshan conducted an in-depth visit to the R&D Center of Shijiazhuang Sihua Pharmaceutical Group, gaining a detailed understanding of the company’s latest developments in new-drug R&D, regulatory review and approval, production quality management, and international expansion. He then held a face-to-face symposium with the company’s leadership and research management personnel, carefully listening to and systematically coordinating solutions for the practical issues the company encounters in registration applications, change filings, and policy alignment.
Shijiazhuang Sihua Pharmaceutical Group is a key pillar enterprise in Hebei Province’s biopharmaceutical industry and has been ranked among the Top 100 Chinese pharmaceutical companies. Over the past two years, the company has closely aligned itself with the province’s and Shijiazhuang’s series of policies and initiatives aimed at fostering high-quality development of the biopharmaceutical sector, rigorously implemented an innovation-driven strategy, and continuously cultivated and expanded new drivers of productivity. As a result, its R&D efficiency and output in specialty generic drugs and active pharmaceutical ingredients have remained at the forefront of the industry, and its integrated “API-plus-formulation” development model has yielded remarkable results.
Wang Fengshan expressed appreciation for the company’s integrated “API-plus-formulation” strategy and its focused development of specialty generic drugs and novel dosage forms. He commended the rapid increase in the number of products approved so far this year and urged the company to further strengthen its innovation capabilities and accelerate the translation of scientific and technological achievements into productive forces.
Wang Fengshan pointed out that our province has thoroughly studied and implemented the spirit of General Secretary Xi Jinping’s important speech during his inspection tour of Hebei, attaching great importance to pharmaceutical safety and the development of the pharmaceutical industry. To this end, a series of policies and measures have been introduced to strengthen top-level design, optimize the business environment, and refine industrial planning, thereby continuously elevating the level of modernization of the province’s biopharmaceutical industry. The Provincial Drug Administration has established and refined a service model characterized by “early engagement, tailored strategies for each enterprise, end-to-end guidance, and coordinated research–review collaboration,” providing personalized guidance for key projects under development in the province and maintaining regular, robust communication with enterprises on critical stages such as clinical trials and registration submissions, all in an effort to fully advance the research and development of innovative drugs.
Wang Fengshan stated that the Provincial Drug Administration will earnestly implement the General Office of the State Council’s “Opinions on Comprehensively Deepening Regulatory Reform of Pharmaceuticals and Medical Devices to Promote High-Quality Development of the Pharmaceutical Industry,” intensify the provision of high-quality policies, and more precisely allocate regulatory resources to cutting-edge technologies, innovative products, advanced manufacturing, and major projects. The agency will continue to optimize the business environment for the pharmaceutical sector, strengthen end-to-end communication and services, help enterprises enhance the quality and efficiency of R&D and innovation, accelerate the market launch of more new and high-quality drugs, and support Hebei’s transformation from a “major pharmaceutical province” into a “strong pharmaceutical province.”
Wang Fengshan urged all pharmaceutical manufacturers to uphold the safety bottom line, balance development with safety, rigorously fulfill their principal responsibilities, and make every effort to ensure the quality and safety of medicines throughout their entire life cycle, thereby laying a solid quality foundation for the industry’s high-quality development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091